Clinical significance of serum miR-25 in non-small-cell lung cancer

Li, J; Yu, Mingming; Liu, Z; Liu, B

doi:10.1080/09674845.2019.1592915

Cited by 18 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreased miR-424-5p expression in hepatocellular carcinoma tissues is independently associated with poor overall survival of the patients, highlighting its value in cancer prognosis (28). In NSCLC, some aberrant miRNAs with dramatic clinical significance have also been identified, such as miR-25 (16) and miR-411 (29).…”

Section: Discussionmentioning

confidence: 99%

“…clinical significance of miRNAs has attracted increasing attention in the diagnosis and prognosis of human malignancies, including NSCLC (16). miR-665 has been reported to be closely associated with pivotal signaling pathways in lung cancer pathogenesis (17), and miR-665 expression in extracellular vesicles is elevated in NSCLC (18).…”

Section: Upregulated Mir-665 Expression Independently Predicts Poor Pmentioning

confidence: 99%

See 1 more Smart Citation

Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Xia

Zhu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the leading causes of global cancer-associated mortality. Aberrant microRNAs (miRs) have been reported to be involved in the pathogenesis of various cancer types. The present study aimed to investigate the expression profile and prognostic value of miR-665 in patients with NSCLC, and to analyze its functional role in tumor progression using NSCLC cells. Reverse transcription-quantitative PCR was used to estimate the expression levels of miR-665. Kaplan-Meier survival curves and Cox regression analysis were performed to evaluate the prognostic value of miR-665. The effects of miR-665 on NSCLC cell proliferation, migration and invasion were examined by cell transfection, and the target gene of miR-665 was explored. miR-665 expression was elevated in the tissue and cell samples of NSCLC. This increased miR-665 expression was associated with lymph node metastasis and TNM stage. An independent association between miR-665 and overall survival was identified in patients with NSCLC. When regulating the expression levels of miR-665 in vitro, NSCLC cell proliferation, migration and invasion were enhanced by overexpression of miR-665, but were inhibited by knockdown of miR-665. The luciferase activity results indicated that the protein tyrosine phosphatase receptor type B (PTPRB) was a direct target of miR-665 in NSCLC cells. The present study provided evidence for the clinical significance of a decreased expression of miR-665 in the prognosis of NSCLC. Upregulation of miR-665 contributed to tumor cell proliferation, migration and invasion by targeting PTPRB, suggesting the potential of miR-665 as a candidate therapeutic target for NSCLC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Upregulated Mir-665 Expression Independently Predicts Poor Pmentioning

confidence: 99%

Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Xia

Zhu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…We used both the tCLN biochip and qRT-PCR to measure the levels of miR-21, miR-25, miR-155, miR-210 and miR-486 in serum samples from 15 normal controls, 32 early stage and 32 late stage NSCLC patients (Figure 2). These five microRNAs were selected because they were reported in at least 5 different studies as promising diagnostic biomarkers for lung cancer (Yang et al, 2017;Yu et al, 2018Yu et al, , 2019Li et al, 2019). Many microRNAs have been reported to be potential circulating biomarkers for lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Non-invasive Detection of Exosomal MicroRNAs via Tethered Cationic Lipoplex Nanoparticles (tCLN) Biochip for Lung Cancer Early Detection

Liu

Kannisto

et al. 2020

Front. Genet.

View full text Add to dashboard Cite

Circulating microRNAs carried by exosomes have emerged as promising diagnostic biomarkers for cancer because of their abundant amount and remarkable stability in body fluids. Exosomal microRNAs in blood are typically quantified using the RNA isolation-qRT-PCR workflow, which cannot distinguish circulating microRNAs secreted by cancer cells from those released by non-tumor cells, making it potentially less sensitive in detecting cancer-specific microRNA biomarkers. We have developed a sensitive and simple tethered cationic lipoplex nanoparticles (tCLN) biochip to detect exosomal microRNAs in human sera. The tCLN biochip allows the discrimination of tumor-derived exosomes from their non-tumor counterparts, and thus achieves higher detection sensitivity and specificity than qRT-PCR. We have demonstrated the clinical utility of the tCLN biochip in lung cancer diagnosis using sera from normal controls, therapy-naive early stage and late stage non-small cell lung cancer (NSCLC) patients. Total five microRNAs (miR-21, miR-25, miR-155, miR-210, and miR-486) were selected as the biomarkers. Each microRNA biomarker measured by tCLN assay showed higher sensitivity and specificity in lung cancer detection than that measured by qRT-PCR. When all five microRNAs were combined, the tCLN assay distinguished normal controls from all NSCLC patients with sensitivity of 0.969, specificity of 0.933 and AUC of 0.970, and provided much better diagnostic accuracy than qRT-PCR (sensitivity = 0.469, specificity = 1.000, AUC = 0.791). Remarkably, the tCLN assay achieved absolute sensitivity and specificity in discriminating early stage NSCLC patients from normal controls, demonstrating its great potential as a liquid biopsy assay for lung cancer early detection.

show abstract

“…Notably, miR-25 levels were strongly decreased in patients who underwent surgery [98] . miR-25 was also analyzed in a study from Li et al [99] who characterized it in the serum of NSCLC patients and, again, miR-25 expression levels were increased in cancer patients compared to controls and were associated with gender, tumor stage, and lymph node metastasis. miR-25 could even be considered an independent prognostic factor for overall and relapse-free survival.…”

Section: Lung Cancermentioning

confidence: 99%

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Quirico¹,

Orso²

2020

CDR

View full text Add to dashboard Cite

In the last decades, progresses in medical oncology have ameliorated the treatment of patients and their outcome. However, further improvements are still necessary, in particular for certain types of tumors such as pancreatic, gastric, and lung cancer as well as acute myeloid leukemia where early detection and monitoring of the disease are crucial for final patient outcome. Liquid biopsy represents a great advance in the field because it is less invasive, less time-consuming, and safer compared to classical biopsies and it can be useful to monitor the evolution of the disease as well as the response of patients to therapy. Liquid biopsy allows the detection of circulating tumor cells, nucleic acids, and exosomes not only in blood but also in different biological fluids: urine, saliva, pleural effusions, cerebrospinal fluid, and stool. Among the potential biomarkers detectable in liquid biopsies, microRNAs (miRNAs) are gaining more and more attention, since they are easily detectable, quite stable in biological fluids, and show high sensitivity. Many data demonstrate that miRNAs alone or in combination with other biomarkers could improve the diagnostic and prognostic power for many different tumors. Despite this, standardization of methods, sample preparation, and analysis remain challenging and a huge effort should be made to address these issues before miRNA biomarkers can enter the clinic. This review summarizes the main findings in the field of circulating miRNAs in both solid and hematological tumors. MIRNAS AS POTENTIAL BIOMARKERSRecently, biomarker research has focused on RNA molecules circulating in the body fluids. RNA analysis is highly sensitive and specific, cheaper than protein analysis, and offers a more dynamic view of cell regulation and states compared to DNA [9] . Long RNA species, however, can be easily degraded by RNAse activity, while shorter RNA molecules, as small non-coding RNAs, are more stable and highly expressed in the blood of cancer patients [10,11] . miRNAs are small non-coding RNAs (19-22 nucleotides) originally discovered in Caenorhabditis elegans in 1993 [12] . In the last decades, miRNAs have been described in all animal models, and some of them resulted

show abstract

Clinical significance of serum miR-25 in non-small-cell lung cancer

Cited by 18 publications

References 33 publications

Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

Non-invasive Detection of Exosomal MicroRNAs via Tethered Cationic Lipoplex Nanoparticles (tCLN) Biochip for Lung Cancer Early Detection

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Contact Info

Product

Resources

About